DOCTOR'S VIEW ARCHIVE
Avandia - An Endocrinologist's Perspective
Steven Nissan and colleagues released an article in the New England Journal of Medicine recently that reviewed the relationship between rosiglitazone (Avandia) and the risk of heart attack and death from cardiovascular causes. Rosiglitazone is one drug in a class of insulin sensitizers known as thiazolidinediones, or TZDs. This class of drugs is commonly prescribed for the treatment of type 2 diabetes and for insulin resistance. The authors of the recent paper reviewed 42 published and unpublished randomized clinical trials, studying patients taking rosiglitazone for a minimum of 24 weeks. Their analysis found a significantly increased risk for heart attack and an even higher risk for overall cardiovascular death from all causes.
While this is of concern, it is important to realize these data were analyzed in a retrospective fashion (looking back at what has happened) as opposed to looking forward with a single study designed to look for the effects of rosiglitazone specifically on the heart as patients continue using the drug into the future. Retrospective studies have inherent flaws in them,, which must be stated and taken into account when the data are reviewed. However, the numbers in the study are convincing, and when translated into "real numbers," there were 86 heart attacks in the rosiglitazone group and 72 in the control group. There were 39 deaths from cardiovascular causes in the rosiglitazone group compared with 22 in the control group.